IL-2- and IL-15-expanded NK cells, which were previously tested in clinical trials for hematological malignancies, showed similar moderate but statistically significant increases in CD107a expression induced by AMP-B at the same concentrations (Figure 2C,D). The gene discussed is IL15; the disease is hematologic disorder.